Company Description
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States.
The company’s products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1’s high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.
It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis.
The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease.
The company serves physicians, physician office laboratories, and national and regional laboratories.
The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC.
It has a research agreement with Harvard’s Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins; and a strategic alliance with Quest Diagnostics, Incorporated.
The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women’s Health Inc. in June 2020.
Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.
| Country | United States |
| Founded | 1993 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Sandra Milligan |
Contact Details
Address: Building III, Suite 100 Austin, Texas 78738 United States | |
| Phone | 512 519 0400 |
| Website | aspirawh.com |
Stock Details
| Ticker Symbol | AWH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000926617 |
| CUSIP Number | 04537Y109 |
| ISIN Number | US04537Y2081 |
| Employer ID | 33-0595156 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Nicole Sandford CPA | Chief Executive Officer, Interim Chief Financial Officer and Director |
| Dr. Sandra Milligan J.D., M.D. | President |
| John Kallassy | Interim Chief Financial Officer |
| Michelle Snider | Senior Vice President of Commercial Strategy and Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 16, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 24, 2024 | 8-K | Current Report |
| Oct 23, 2024 | 8-K | Current Report |
| Oct 18, 2024 | 8-K | Current Report |
| Sep 13, 2024 | 8-K | Current Report |